Hudson Bay Capital Management LP Aurinia Pharmaceuticals Inc. Transaction History

Hudson Bay Capital Management LP

  • $18.6 Billion
  • Q2 2024

A detailed history of Hudson Bay Capital Management LP transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 339,900 shares of AUPH stock, worth $2.47 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
339,900
Previous 290,400 17.05%
Holding current value
$2.47 Million
Previous $1.45 Million 33.43%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$4.81 - $5.78 $238,094 - $286,110
49,500 Added 17.05%
339,900 $1.94 Million
Q1 2024

May 15, 2024
BUY
$4.93 - $9.31 $975,647 - $1.84 Million
197,900 Added 213.95%
290,400 $1.45 Million
Q4 2023

Feb 14, 2024
SELL
$7.13 - $9.49 $456,205 - $607,208
-63,984 Reduced 40.89%
92,500 $831,000
Q3 2023

Nov 14, 2023
BUY
$7.77 - $12.27 $194,250 - $306,750
25,000 Added 19.01%
156,484 $1.22 Million
Q2 2023

Aug 14, 2023
SELL
$8.96 - $11.69 $985,600 - $1.29 Million
-110,000 Reduced 45.55%
131,484 $1.27 Million
Q1 2023

May 15, 2023
SELL
$5.94 - $11.27 $831,600 - $1.58 Million
-140,000 Reduced 36.7%
241,484 $2.65 Million
Q4 2022

Feb 14, 2023
BUY
$4.11 - $8.14 $274,548 - $543,752
66,800 Added 21.23%
381,484 $1.65 Million
Q3 2022

Nov 14, 2022
BUY
$6.66 - $12.39 $920,412 - $1.71 Million
138,200 Added 78.31%
314,684 $2.37 Million
Q2 2022

Aug 12, 2022
BUY
$8.95 - $12.8 $134,250 - $192,000
15,000 Added 9.29%
176,484 $1.77 Million
Q1 2022

May 16, 2022
BUY
$10.05 - $22.48 $621,934 - $1.39 Million
61,884 Added 62.13%
161,484 $2 Million
Q4 2021

Feb 14, 2022
SELL
$17.78 - $33.08 $2.23 Million - $4.15 Million
-125,400 Reduced 55.73%
99,600 $2.28 Million
Q3 2021

Nov 15, 2021
SELL
$10.93 - $23.55 $4.48 Million - $9.66 Million
-410,000 Reduced 64.57%
225,000 $4.98 Million
Q2 2021

Aug 16, 2021
SELL
$10.0 - $14.52 $1.4 Million - $2.03 Million
-140,000 Reduced 18.06%
635,000 $8.23 Million
Q1 2021

May 14, 2021
BUY
$12.3 - $18.73 $922,500 - $1.4 Million
75,000 Added 10.71%
775,000 $10.1 Million
Q4 2020

Feb 12, 2021
BUY
$12.94 - $16.05 $1.88 Million - $2.33 Million
145,000 Added 26.13%
700,000 $9.68 Million
Q3 2020

Nov 12, 2020
BUY
$13.19 - $16.66 $2.37 Million - $3 Million
180,000 Added 48.0%
555,000 $8.18 Million
Q2 2020

Aug 12, 2020
SELL
$14.12 - $18.33 $494,200 - $641,549
-35,000 Reduced 8.54%
375,000 $6.09 Million
Q1 2020

May 14, 2020
BUY
$11.34 - $21.46 $680,400 - $1.29 Million
60,000 Added 17.14%
410,000 $5.95 Million
Q4 2019

Feb 12, 2020
SELL
$3.88 - $21.42 $194,000 - $1.07 Million
-50,000 Reduced 12.5%
350,000 $7.09 Million
Q3 2019

Nov 13, 2019
SELL
$5.34 - $6.59 $1.04 Million - $1.29 Million
-195,000 Reduced 32.77%
400,000 $2.14 Million
Q2 2019

Aug 14, 2019
BUY
$6.05 - $6.75 $1.1 Million - $1.23 Million
182,500 Added 44.24%
595,000 $3.92 Million
Q1 2019

May 15, 2019
BUY
$6.06 - $7.64 $833,250 - $1.05 Million
137,500 Added 50.0%
412,500 $2.68 Million
Q4 2018

Feb 13, 2019
SELL
$5.08 - $6.83 $342,900 - $461,025
-67,500 Reduced 19.71%
275,000 $1.88 Million
Q3 2018

Nov 14, 2018
BUY
$5.27 - $6.64 $592,875 - $747,000
112,500 Added 48.91%
342,500 $2.27 Million
Q2 2018

Aug 13, 2018
SELL
$5.06 - $6.36 $354,200 - $445,200
-70,000 Reduced 23.33%
230,000 $1.3 Million
Q1 2018

May 14, 2018
SELL
$4.85 - $5.99 $727,500 - $898,500
-150,000 Reduced 33.33%
300,000 $1.56 Million
Q4 2017

Feb 12, 2018
BUY
$4.53 - $7.09 $339,750 - $531,750
75,000 Added 20.0%
450,000 $2.04 Million
Q3 2017

Nov 13, 2017
BUY
$5.71 - $6.9 $2.14 Million - $2.59 Million
375,000
375,000 $2.35 Million

Others Institutions Holding AUPH

# of Institutions
191
Shares Held
56.2M
Call Options Held
499K
Put Options Held
637K
View Full List

About Aurinia Pharmaceuticals Inc.

AUPH Quotes by TradingView
  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.03B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email